Madison, WI based InvivoSciences (IVS) is a pre-clinical-stage biotech company developing heart failure (HF) therapeutics using a precision medicine approach to extend lifespan of patients. Our mission is to cure heart failure one gene at a time. It is driven by the urgency of heart failure patients who need more effective and safe therapies.
Our Breakthrough platform discovery technology rapidly analyzes safety and efficacy profile of a given treatment for specific patient group cost-effectively before expensive trials. IVS matchmakes the best treatment for the patient group and expedites the early discovery, clinical trials, and post-product launch monitoring, bringing tremendous value before investing significant resources in human trials.
We have leveraged our breakthrough precision medicine discovery platform using patient-derived human micro heart on a chip Nuheart TM to identify and validate multiple drug pipelines rapidly.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform can lead to meaningfully better outcomes for heart failure patients, which we refer as InvivoSciences’ discovery engine to develop target therapies. To help move our programs forward InvivoSciences is seeking world class life science investors and strategic partners.